Back to top
more

Ecolab (ECL)

(Delayed Data from NYSE)

$253.55 USD

253.55
990,657

-1.78 (-0.70%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $253.42 -0.13 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 14% (215 out of 251)

Industry: Chemical - Specialty

Better trading starts here.

Zacks News

Philips' (PHG) Gets FDA Recall for Trilogy Ventilator Glitch

Philips' (PHG) software update for Trilogy Evo ventilators is set to mitigate a possible power malfunction and gets FDA Class I recall identification, as it may cause serious harm.

FMC Corp (FMC) Teams Up With AgroSpheres for Bioinsecticides

FMC partners with AgroSpheres to accelerate the development of innovative bioinsecticides, enhancing sustainable crop protection and reinforcing FMC's industry leadership.

Air Products (APD) Unveils PRISM LNG Membrane Separator

Air Products' (APD) Membrane Solutions specializes in hollow fiber membrane separators and onsite gas generation.

DuPont (DD) to Showcase Advanced Circuit Materials in Shanghai

The new technology solutions highlight DuPont's (DD) capacity to generate innovation and provide value in collaboration with industry leaders in the Artificial Intelligence field.

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Three Reasons to Retain Integer Holdings (ITGR) Stock for Now

Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.

Catalent's (CTLT) Latest Partnership to Boost Clinical Trials

Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.

Orthofix Medical's (OFIX) Telescopic Nail Gets FDA Clearance

Orthofix Medical (OFIX) announces the FDA clearance of its Rodeo Telescopic Nail, which is likely to aid in curing fractures or abnormalities in individuals with osteogenesis imperfecta.

DuPont (DD) Introduces Tyvek Trifecta Breather Membrane

DuPont (DD) Tyvek Trifecta complements the DuPont AirGuard A2 FR AVCL, resulting in a comprehensive A-rated membrane system.

Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition

Neogen (NEOG) faces intense competition from companies ranging from small businesses to divisions of large multinational companies.

PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up

PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.

LyondellBasell (LYB) Announces Review of European Operations

LyondellBasell (LYB) is conducting a strategic review of its European operations, focusing on reinvesting in high-return businesses.

Air Products (APD) AP-DMR LNG Process Passes Performance Test

Air Products' (APD) innovative AP-DMR LNG Process was chosen for its high efficiency, dependable operation and small footprint.

QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall

QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.

Ashland (ASH) to Divest Nutraceuticals Business to Turnspire

Ashland (ASH) is set to sell its nutraceuticals business to Turnspire Capital Partners, with the deal expected to close in third-quarter 2024.

OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y

OPKO Health's (OPK) first-quarter results reflect soft performances despite robust RAYALDEE sales and strength in the Pharmaceuticals segment.

McKesson (MCK) Q4 Earnings Miss Estimates, Revenues Up Y/Y

McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.

Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up

Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.

Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up

Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.

Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up

Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.

Barrick (GOLD) Announces Partnership With Geophysx Jamaica

The agreement initially grants Barrick (GOLD) access to about 4,000 square kilometers of consolidated land positions across the country.

DOW to Sell Flexible Packaging Laminating Adhesives Business

This deal allows DOW to focus even more on core, high-value downstream operations.

Are You Looking for a Top Momentum Pick? Why Ecolab (ECL) is a Great Choice

Does Ecolab (ECL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal

Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.